Immunovant Gets Positive Data From Graves' Disease Treatment Trial
December 20 2023 - 4:40PM
Dow Jones News
By Sabela Ojea
Immunovant said it received positive data from its ongoing
24-week Phase 2 clinical trial for its batoclimab treatment for
Graves' disease.
The clinical-stage immunology company on Wednesday said the
trial results in patients with Graves' disease meaningfully
exceeded 50% response rates.
Batoclimab was generally well tolerated with no new safety
signals observed in the initial data set.
Graves' disease is an immune system disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:25 ET (22:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From May 2024 to Jun 2024
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From Jun 2023 to Jun 2024